PhRMA Delegation Meets China Pharmaceutical Organizations
This article was originally published in PharmAsia News
Executive Summary
Representatives from the Pharmaceutical Research and Manufacturers of America recently attended an international summit in Beijing on new drug R&D policies and practices hosted by the Healthcare Policy Research Center of Chinese Pharmaceutical Association. The center expressed the wish of strengthening both countries' cooperation in drug production to the American delegation, which included top-level executives from key multinational companies such as Bristol-Myers Squibb, Lilly, Genzyme, GlaxoSmithKline, MSD Pharma (Merck's India arm), Novartis, Pfizer, Schering-Plough and Wyeth. The U.S. group held exchanges with officials from China's State FDA and the Ministry of Health on supervisory issues about developing new drugs globally and conducting multicenter clinical trials. Members from China Health & Medical Development Foundation, Chinese Pharmaceutical Association and China Pharmaceutical Industry Association also joined in discussions to boost collaboration. (Click here for more - Chinese Language)